Asian Spectator

Men's Weekly

.

AweMed Series Sponsors Eczema Family Day 2025 to Support Singapore’s Sensitive Skin Community

SINGAPORE - Media OutReach Newswire - 3 July 2025 - AweMed®, a skincare brand developed in collaboration with local dermatologists and paediatricians, sponsored the Eczema Family Day 2025—a...

GMA Brand Awareness Expands Worldwide with Strategic Partners ...

TAIPEI, Taiwan, July 12, 2019/PRNewswire-AsiaNet/-- Golden Melody Awards & Festival 2019 has concluded on June 29th. Festival programs and design were expanded to more strategic alliance...

Crowdsourced security use jumps to 73 percent as business down...

REDWOOD CITY, Calif., April 27, 2021 /PRNewswire-AsiaNet/ -- -- Business downtime overtook breaches as the No.1 concern for security professionals as cybercrime reports surged 69 percent las...

Wipro Expands Sports, Entertainment, Retail and Transport Offe...

NEW YORK and BANGALORE, India, December 13, 2021 /PRNewswire-AsiaNet/ -- - Expanded strategic partnership with Cisco positions Wipro as a leader in providing solutions & services to the...

9 in 10 Malaysians Choose Shopee for Safe Online Shopping

#ShopSafeWithShopee Reveals Malaysian Savviness in Avoiding ScamsKUALA LUMPUR, MALAYSIA - Media OutReach - 12 October 2023 - Shopee, the leading e-commerce platform in Southeast Asia and Ta...

VisionNav debuts Autonomous Forklift at CeMAT Australia 2022

MELBOURNE, Australia, July 22, 2022 /PRNewswire-AsiaNet/ -- As a key part of its global tour, VisionNav debuts its iconic autonomous forklift for logistics automation and the Bright Eyes env...

The Adecco Group Names John Morgan As President Of LHH

NEW YORK, May 6, 2021 /PRNewswire-AsiaNet/ -- -- Current LHH President Ranjit de Sousa to step down at the end of June LHH has appointed John Morgan as President effective July 1. Mr. Morgan...

Citri Mobile Expands IRP-Certified iPhone Repairs with New Singapore Outlet in Tampines

SINGAPORE - Media OutReach Newswire - 13 June 2025 - Mobile devices play a vital role in Singapore's infrastructure, supporting communication, education, logistics, and work-related functio...

OneMALL Announces Limited Time Offer for Setup of Online Stores

KUALA LUMPUR, MALAYSIA - Media OutReach - 14 June 2021 - Small and medium-sized enterprises (SMEs), micro SMEs and individual entrepreneurs have to bear the brunt of the lockdown imposed ...

Fujitsu Improves Efficiency in Cancer Genomic Medicine in Joint AI Research with the Institute of Medical Science at the University of Tokyo

Fujitsu Improves Efficiency in Cancer Genomic Medicine in Joint AI Research with the Institute of Medical Science at the University of Tokyo

KAWASAKI, Japan, Nov 7, 2019 - (JCN Newswire) - Fujitsu has announced the results of a joint research project it has been conducting with the Institute of Medical Science at the University of Tokyo since April 2018. As part of this joint research, Fujitsu Laboratories Ltd. has successfully developed and verified AI technology to improve the efficiency of treatment planning in cancer genomic medicine, demonstrating its effectiveness through verification experiments at the Institute of Medical Science at the University of Tokyo.

Fujitsu Improves Efficiency in Cancer Genomic Medicine in Joint AI Research with the Institute of Medical Science at the University of Tokyo

Figure 1: Positioning of the Investigation of Treatment Plans in Cancer Genomic Medicine

Fujitsu Improves Efficiency in Cancer Genomic Medicine in Joint AI Research with the Institute of Medical Science at the University of Tokyo

Figure 2: Effect of introducing this technology

In the field of cancer genomic medicine, creating treatment plans derived from genomic information remains a costly and time-consuming process. The newly developed technology extracts from a vast body of research and academic papers to generate a knowledge graph of cancer genomic medicine that can be used for creating treatment plans, including the effects of a given course of treatment. Verification trial experiments using this technology have allowed the Department of Hematology and Oncology at the Institute of Medical Science, the University of Tokyo to reduce the amount of work required to determine a treatment plan for acute myeloid leukemia by more than half, delivering improved efficiency.

Moving forward, Fujitsu Laboratories will support the work of medical doctors by expanding the technology to deal with a greater range of cancer types and contribute to the overall advancement of cancer genomic medicine.

The technology will be on display at "Fujitsu Forum Munich 2019" in Munich, Germany, from Wednesday, November 6.

Development Background

The goal of cancer genomic medicine is to provide optimal medical care for each patient by identifying genomic mutations in cancer patients and predicting the likelihood of disease, as well as drug response and side effects. Starting from June 2019 in Japan, cancer gene panel testing has been covered by health insurance, and industry experts anticipate an increasing number of patients to seek further testing.

Presently, in the field of cancer genomic medicine, it remains necessary for specialist physicians to painstakingly search for relevant articles one by one from a database and determine appropriate treatment methods as well as their effects on the patient (Figure 1). To address these challenges, Fujitsu Laboratories and the Institute of Medical Science at the University of Tokyo's launched a joint AI research project beginning in April 2018 to improve the efficiency and sophistication of the work of physicians specializing in cancer genomics, subsequently conducting a verification trial for the technology.

Outline of the Verification Trials

1. Trial PeriodJuly 2018 to September 2019

2. Trial LocationDepartment of Hematology and Oncology, the Institute of Medical Science at the University of Tokyo

3. Developed technologyThe new technology automatically generates a database of knowledge on the relationship between gene mutations and therapeutic drugs, and the relationship between therapeutic drugs and their effects, drawing from medical papers. This is accomplished by integrating Fujitsu's AI technology for language processing, which identifies terms and phrases used in research papers from context, as well as insight of information needed to discuss treatment policies identified by the Institute of Medical Science at the University of Tokyo.

4. Verification Trial DetailsWith the newly developed technology, 2.4 million elements of relationships from 860,000 medical papers are automatically extracted as knowledge to construct a knowledge graph database for cancer genomic medicine.

In this study, the time required for 4 physicians specializing in hematological malignancies at the Institute of Medical Science at the University of Tokyo to search and examine papers using the technology based on past cases of acute myeloid leukemia is measured, and the efficiency of examination work with and without the newly developed technology is evaluated(1) (Fig. 2). For this verification experiment, a database developed by Fujitsu Limited in cooperation with the Japan Agency for Medical Research and Development as part of the "Program for an Integrated Database of Clinical and Genomic Information"(2) is used as part of the knowledge graph.

5. ResultsThe technology reduced the burden of reading the entire paper by presenting the knowledge extracted from each paper and enabled users to focus on pertinent aspects of research alone. As a result, it was confirmed that the new technology can reduce the amount of time spent on this task by more than half, compared with the average of about 30 minutes per each study it took in the past. At present, it is estimated that more than 12,000 people suffer from leukemia annually in Japan(3), and if genomic medical treatments are administered to all of them using this new technology, the 6,000 hours of examination work normally required for experts can be shortened to 3,000 hours or less, considerably expediting the process of determining the a treatment appropriate for each patient.Future Plans

Technology developed at Fujitsu Laboratories to explain the reason and rationale behind AI decision-making(4) is to be used in conjunction with this technology in order to further improve the efficiency of the genomic mutation curation process. Fujitsu will further use the knowledge graph for precision medicine developed through this joint research to improve the efficiency of the study of gene mutations for a wide range of cancer types, and actively promote the development of cancer genomics in clinical practice.

Comment from our Research Partners

Professor Seiya Imoto, Health Intelligence Center, the Institute of Medical Science at the University of Tokyo

"The promise of new genomic medicine, which harness the wealth of information contained in the human genome, remains extremely difficult to fully exploit given the limited time of doctors. This trial demonstrates that AI technology can be used to support planning for treatments that target blood tumors, helping physicians to process the research literature that forms the basis of therapeutic best practices in less than half the time it has previously taken. We hope that the further development of AI technology for various genome-related medical contexts will enable more patients to receive precision medicine, contributing to the realization of medical care in Japan that can beat cancer."

(1) The efficiency of examination work with and without the newly developed technology is evaluatedIn the actual verification work, apart from searching relevant research papers, doctors engage in various additional work, such as interpreting sequence data, analyzing data, and creating reports.(2) The Japan Agency for Medical Research and Development as part of the "Program for an Integrated Database of Clinical and Genomic Information"A program based on the interim report of the Council for Promotion of Genome Medicine Implementation, to verify the relationship between genome information and disease specificity and clinical characteristics, to develop a database that comprehensively handles clinical information and genomic information that can be used for clinical and research purposes, and to promote advanced research and development that makes use of the research infrastructure.(3) At present, it is estimated that more than 12,000 people suffer from leukemia annually in JapanCancer Information Service, National Cancer Research Center "Cancer registry and statistics"(Source).(4) Press Release"Fujitsu Fuses Deep Tensor with Knowledge Graph to Explain Reason and Basis Behind AI-Generated Findings" (September 20, 2017)

About Fujitsu

Fujitsu is the leading Japanese information and communication technology (ICT) company, offering a full range of technology products, solutions, and services. Approximately 132,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (Code: 6702) reported consolidated revenues of 4.0 trillion yen (US $36 billion) for the fiscal year ended March 31, 2019. For more information, please see www.fujitsu.com.

About Fujitsu Laboratories

Founded in 1968 as a wholly owned subsidiary of Fujitsu Limited, Fujitsu Laboratories Ltd. is one of the premier research centers in the world. With a global network of laboratories in Japan, China, the United States and Europe, the organization conducts a wide range of basic and applied research in the areas of Next-generation Services, Computer Servers, Networks, Electronic Devices, and Advanced Materials. For more information, please see http://www.fujitsu.com/jp/group/labs/en/.

Technical ContactsFujitsu Laboratories Ltd.Artificial Intelligence LaboratoryE-mail: qa_fy2019@ml.labs.fujitsu.com

Copyright 2019 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Terjebak budaya sungkan: Enggan komplain bisa menghambat perbaikan pelayanan publik

Sejumlah orang sedang menunggu antrean di ruangan di suatu fasilitas pelayanan publik di Jakarta. Zulkarnain.B/Shutterstock● Masih banyak masyarakat enggan komplain karena budaya sungkan dan tid...

Kamu nyaman curhat dengan AI? Hati-hati kena gangguan mental

Seorang perempuan sedang duduk sambil curhat dengan robot humanoid AI di sebuah ruang tamu.VesnaArt/Shutterstock● Kaum muda kini sering menjadikan ‘chatbot’ AI sebagai teman curhat.&...

Cemas saat berulang tahun? Simak tip psikolog untuk hadapi ‘birthday blues’

DavideAngelini/ShutterstockUlang tahun biasanya jadi momen membahagiakan penuh dengan tawa, perayaan, dan hadiah. Namun, tak jarang menjelang ulang tahun, kita justru merasa sedih.Ulang tahun dapat me...